Document is current
Any future updates will be listed below
-
Authors
Stener-Victorin, Elisabet https://orcid.org/0000-0002-3424-1502
Carlsson, Sofia https://orcid.org/0000-0002-9497-2331
Hagström, Hannes https://orcid.org/0000-0002-8474-1759
Taebnia, Nayere https://orcid.org/0000-0003-0707-278X
-
Funding
Funding for this research was provided by:
Distinguished Investigator Grant – Endocrinology and Metabolism, Novo Nordisk Foundation (NNF22OC0072904)
Distinguished Investigator Grant – Endocrinology and Metabolism, Novo Nordisk Foundation (project grant no. NNF25OC010478)
Karolinska Institute Research Foundation Grant (2024-03194)
Karolinska Institutet KID funding (2023-0005 (ESV))
Swedish Medical Research Council (2022-00550 (ESV))
Swedish Medical Research Council (2022-00811 (SC))
Diabetes Foundation (DIA2024-860 (ESV))
Diabetes Foundation (DIA2024-908 (SC))
Karolinska Institute
- License Information
-
More Information
Article History
Received: 30 January 2026
Accepted: 14 April 2026
First Online: 5 June 2026
Funding
: Open access funding provided by Karolinska Institute. Work in the authors’ laboratories is supported by the Swedish Medical Research Council (project no. 2022-00550 [ESV]), 2022-00811 [SC]); a Distinguished Investigator Grant – Endocrinology and Metabolism, Novo Nordisk Foundation (NNF22OC0072904 and project grant no. NNF25OC0104784 [ESV]); the Diabetes Foundation (DIA2024-860 [ESV], DIA2024-908 [SC]); and Karolinska Institutet KID funding (2023-0005 [ESV]). NT acknowledges support from a Karolinska Institute Research Foundation Grant (2024-03194) and special grants for young scientists.
: ESV’s department has received funding from Alnylam and Ferring. She has served as consultant and speaker for Alnylam and Exeltis. HH’s institutions have received research funding from AstraZeneca, Echosens, Gilead, Intercept, MSD, Novo Nordisk, Takeda and Pfizer. He has served as consultant or speaker or on advisory boards for AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, GSK, Echosens, Ipsen, MSD and Novo Nordisk and has been part of hepatic events adjudication committees for Arrowhead, Boehringer Ingelheim, KOWA and GW Pharmaceuticals. NT serves as a national expert and member of the Swedish Institute for Standards (SIS). The authors declare that there are no other relationships or activities that might bias, or be perceived to bias, their work.
: All authors were responsible for drafting and critically reviewing the article for intellectual content. NT designed and prepared Figs and . All authors approved the final version of the article to be published.
